IN2012DN00572A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00572A
IN2012DN00572A IN572DEN2012A IN2012DN00572A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A IN 572DEN2012 A IN572DEN2012 A IN 572DEN2012A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A
Authority
IN
India
Prior art keywords
compositions
treating
methods
provides
present
Prior art date
Application number
Other languages
English (en)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Irm Llc filed Critical Scripps Research Inst
Publication of IN2012DN00572A publication Critical patent/IN2012DN00572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN572DEN2012 2009-07-14 2010-07-13 IN2012DN00572A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Publications (1)

Publication Number Publication Date
IN2012DN00572A true IN2012DN00572A (zh) 2015-06-12

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572DEN2012 IN2012DN00572A (zh) 2009-07-14 2010-07-13

Country Status (31)

Country Link
US (4) US9139633B2 (zh)
EP (1) EP2453921B1 (zh)
JP (1) JP5602850B2 (zh)
KR (3) KR20180000337A (zh)
CN (2) CN102625830B (zh)
AU (1) AU2010273570B2 (zh)
BR (1) BR112012000914B8 (zh)
CA (1) CA2767826C (zh)
CL (1) CL2012000091A1 (zh)
CO (1) CO6491059A2 (zh)
CR (1) CR20120024A (zh)
CU (1) CU24042B1 (zh)
EA (1) EA023073B1 (zh)
EC (1) ECSP12011604A (zh)
ES (1) ES2541217T3 (zh)
GT (1) GT201200011A (zh)
HK (1) HK1164169A1 (zh)
IL (2) IL217383A (zh)
IN (1) IN2012DN00572A (zh)
MA (1) MA33423B1 (zh)
MX (1) MX2012000707A (zh)
MY (1) MY160951A (zh)
NZ (1) NZ597306A (zh)
PE (2) PE20120570A1 (zh)
PL (1) PL2453921T3 (zh)
PT (1) PT2453921E (zh)
SG (1) SG177318A1 (zh)
TN (1) TN2011000655A1 (zh)
UA (1) UA104031C2 (zh)
WO (1) WO2011008773A2 (zh)
ZA (1) ZA201200078B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602850B2 (ja) * 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN110198441B (zh) 2011-11-08 2022-01-11 韩国电子通信研究院 用于共享候选者列表的方法和装置
PT2864360T (pt) 2012-06-25 2018-01-05 The Brigham And Women`S Hospital Inc Terapêuticas dirigidas ao alvo
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CA2904160C (en) 2013-03-15 2022-08-23 The California Institute For Biomedical Research Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis
JO3563B1 (ar) 2014-05-13 2020-07-05 Novartis Ag مركبات وتركيبات لتحفيز تكوين الغضاريف
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
JP2019535707A (ja) * 2016-11-14 2019-12-12 ノバルティス アーゲー 軟骨損傷および関節炎の処置のための方法および組成物
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
EP3891154B1 (en) 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CA2375458A1 (en) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2002224377B2 (en) 2000-10-16 2007-07-19 Genentech, Inc. Methods of Treatment Using WISP Polypeptides
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN101905024A (zh) * 2001-11-16 2010-12-08 杰南技术公司 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
WO2004022630A2 (en) * 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
ATE488588T1 (de) * 2003-03-10 2010-12-15 Japan Science & Tech Agency Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5269411B2 (ja) * 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
EP2155862A2 (en) * 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
JP5602850B2 (ja) * 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular

Also Published As

Publication number Publication date
CA2767826A1 (en) 2011-01-20
US20200108122A1 (en) 2020-04-09
PE20120570A1 (es) 2012-05-19
EA023073B1 (ru) 2016-04-29
BR112012000914B8 (pt) 2021-05-25
EA201200118A1 (ru) 2012-09-28
CO6491059A2 (es) 2012-07-31
EP2453921A4 (en) 2012-12-19
CN105601728B (zh) 2020-01-10
CN102625830A (zh) 2012-08-01
US9139633B2 (en) 2015-09-22
CU24042B1 (es) 2014-11-27
MY160951A (en) 2017-03-31
EP2453921B1 (en) 2015-05-27
JP5602850B2 (ja) 2014-10-08
US11241482B2 (en) 2022-02-08
US20190000922A1 (en) 2019-01-03
IL217383A (en) 2016-08-31
KR20120029472A (ko) 2012-03-26
BR112012000914A8 (pt) 2017-12-19
US10064918B2 (en) 2018-09-04
SG177318A1 (en) 2012-03-29
CL2012000091A1 (es) 2012-10-26
WO2011008773A3 (en) 2011-08-25
EP2453921A2 (en) 2012-05-23
CR20120024A (es) 2012-06-11
ZA201200078B (en) 2013-01-30
CU20120007A7 (es) 2013-02-26
TN2011000655A1 (en) 2013-05-24
PL2453921T3 (pl) 2015-11-30
HK1164169A1 (zh) 2012-09-21
KR20160015403A (ko) 2016-02-12
IL217383A0 (en) 2012-02-29
AU2010273570B2 (en) 2014-07-03
ECSP12011604A (es) 2012-06-29
GT201200011A (es) 2013-12-10
PT2453921E (pt) 2015-09-25
MX2012000707A (es) 2012-03-21
CA2767826C (en) 2015-11-24
US20120177644A1 (en) 2012-07-12
CN102625830B (zh) 2016-03-02
BR112012000914A2 (pt) 2017-08-08
KR101590834B1 (ko) 2016-02-12
IL247310B (en) 2018-04-30
ES2541217T3 (es) 2015-07-16
AU2010273570A1 (en) 2012-02-02
NZ597306A (en) 2014-03-28
KR20180000337A (ko) 2018-01-02
CN105601728A (zh) 2016-05-25
US10555990B2 (en) 2020-02-11
UA104031C2 (uk) 2013-12-25
JP2012533549A (ja) 2012-12-27
PE20160507A1 (es) 2016-05-20
MA33423B1 (fr) 2012-07-03
BR112012000914B1 (pt) 2021-04-06
WO2011008773A2 (en) 2011-01-20
US20160213748A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
IN2012DN00572A (zh)
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
IN2012DN03883A (zh)
MY172372A (en) Compositions and methods for lowering triglycerides
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
IN2012DN02624A (zh)
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2012017321A3 (en) Treatment for dyslipidemia
WO2010037095A3 (en) Agents and methods for the treatment of cancer
MX2010002950A (es) Metodos y composiciones para deteccion de ehrlichia chaffeensis (vlpt).
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MY165088A (en) Pharmaceutical compositions comprising alisporivir